SEC Comment Letter 0000000000-23-006273 to OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: June 12, 2023 · CIK: 0001849296 · Accession: 0000000000-23-006273
AI Filing Summary & Sentiment
File numbers found in text: 333-272516
Letter
United States securities and exchange commission logo June 12, 2023 Gary Jacob, Ph.D. Chief Executive Officer and Director OKYO Pharma Ltd 420 Lexington Avenue, Suite 1405 New York, NY 10170 Re:OKYO Pharma Ltd Registration Statement on Form F-3 Filed June 8, 2023 File No. 333-272516 Dear Gary Jacob: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Fessler, Esq.
Show Raw Text
United States securities and exchange commission logo
June 12, 2023
Gary Jacob, Ph.D.
Chief Executive Officer and Director
OKYO Pharma Ltd
420 Lexington Avenue, Suite 1405
New York, NY 10170
Re:OKYO Pharma Ltd
Registration Statement on Form F-3
Filed June 8, 2023
File No. 333-272516
Dear Gary Jacob:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Fessler, Esq.